Neurocrine Biosciences (NBIX) investor relations material

Executive summary

• Annual meeting scheduled for May 27, 2026, with voting available online or in person.

• Shareholders are encouraged to review proxy materials and vote by May 26, 2026.

Voting matters and shareholder proposals

• Election of three Class III director nominees for a three-year term: Kevin C. Gorman, Gary A. Lyons, and Johanna Mercier.

• Advisory vote on executive compensation (say-on-pay) is on the agenda.

• Proposal to amend the 2025 Equity Incentive Plan to add 4,000,000 shares for issuance.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Proxyholders have discretionary authority to vote on other business or substitute nominees if needed.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals and nominees.